Publication dans British Journal of Cancer : Preclinical study of 212Pb-radioimmunotherapy targeting CD20 in Non-Hodgkin Lymphoma.

The CARAT project “Consortium for Applications in Radio Alpha Therapies”, funded by BPI France, aimed to carry out preclinical studies with Lead-212, in collaboration with the University Hospital of Limoges and Orano Med on malignant hemopathies.

The proof of concept for the efficacy of Lead-212 radioimmunotherapy (RIT) in a preclinical model of lymphoma was published in the British Journal of Cancer this month (October 2021).

This study in an experimental mouse model mimicking lymphoma has shown that lead-212 radioimmunotherapy enables tumor regression and highlights the potential of lead-212 RIT in non-Hodgkin lymphoma.


Full text link